|
1
|
Hartke J, Johnson M and Ghabril M: The
diagnosis and treatment of hepatocellular carcinoma. Semin Diagn
Pathol. 34:153–159. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rumgay H, Arnold M, Ferlay J, Lesi O,
Cabasag CJ, Vignat J, Laversanne M, McGlynn KA and Soerjomataram I:
Global burden of primary liver cancer in 2020 and predictions to
2040. J Hepatol. 77:1598–1606. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li C and He WQ: Comparison of primary
liver cancer mortality estimates from World Health Organization,
global burden disease and global cancer observatory. Liver Int.
42:2299–2316. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clark T, Maximin S, Meier J, Pokharel S
and Bhargava P: Hepatocellular carcinoma: Review of epidemiology,
screening, imaging diagnosis, response assessment, and treatment.
Curr Probl Diagn Radiol. 44:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang KV, Chen JD, Wu WT, Huang KC, Hsu CT
and Han DS: Association between loss of skeletal muscle mass and
mortality and tumor recurrence in hepatocellular carcinoma: A
systematic review and meta-analysis. Liver Cancer. 7:90–103. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Papadopoulou SK: Sarcopenia: A
contemporary health problem among older adult populations.
Nutrients. 12:12932020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rier HN, Jager A, Sleijfer S, Maier AB and
Levin MD: The prevalence and prognostic value of low muscle mass in
cancer patients: A review of the literature. Oncologist.
21:1396–1409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gibson DJ, Burden ST, Strauss BJ, Todd C
and Lal S: The role of computed tomography in evaluating body
composition and the influence of reduced muscle mass on clinical
outcome in abdominal malignancy: A systematic review. Eur J Clin
Nutr. 69:1079–1086. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shachar SS, Williams GR, Muss HB and
Nishijima TF: Prognostic value of sarcopenia in adults with solid
tumours: A meta-analysis and systematic review. Eur J Cancer.
57:58–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moher D, Shamseer L, Clarke M, Ghersi D,
Liberati A, Petticrew M, Shekelle P and Stewart LA; PRISMA-P Group,
: Preferred reporting items for systematic review and meta-analysis
protocols (PRISMA-P) 2015 statement. Syst Rev. 4:12015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lo CK, Mertz D and Loeb M:
Newcastle-Ottawa Scale: Comparing reviewers' to authors'
assessments. BMC Med Res Methodol. 14:452014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borenstein M, Hedges LV, Higgins JP and
Rothstein HR: A basic introduction to fixed-effect and
random-effects models for meta-analysis. Res Synth Methods.
1:97–111. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duval S and Tweedie R: Trim and fill: A
simple funnel-plot-based method of testing and adjusting for
publication bias in meta-analysis. Biometrics. 56:455–463. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alsebaey A, Sabry A, Rashed HS, Elsabaawy
MM, Ragab A, Aly RA and Badran H: MELD-sarcopenia is better than
ALBI and MELD score in patients with hepatocellular carcinoma
awaiting liver transplantation. Asian Pac J Cancer Prev.
22:2005–2009. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akce M, Liu Y, Zakka KM, Martini DJ,
Draper A, Alese OB, Shaib WL, Wu C, Wedd J, Sellers MT, et al: The
impact of inflammatory biomarkers, BMI, and sarcopenia on survival
in advanced hepatocellular carcinoma treated with immunotherapy. J
Clin Oncol. 38 (4 Suppl):S5532020. View Article : Google Scholar
|
|
18
|
Begini P, Gigante E, Antonelli G,
Carbonetti F, Iannicelli E, Anania G, Imperatrice B, Pellicelli AM,
Fave GD and Marignani M: Sarcopenia predicts reduced survival in
patients with hepatocellular carcinoma at first diagnosis. Ann
Hepatol. 16:107–114. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong D, Shi JY, Shang X, Liu B, Xu WL, Cui
GZ and Wang NY: Prognostic significance of sarcopenia in patients
with hepatocellular carcinoma treated with lenvatinib: A
retrospective analysis. Medicine (Baltimore). 101:e286802022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guichet PL, Taslakian B, Zhan C, Aaltonen
E, Farquharson S, Hickey R, Horn CJ and Gross JS: MRI-derived
sarcopenia associated with increased mortality following yttrium-90
radioembolization of hepatocellular carcinoma. Cardiovasc Intervent
Radiol. 44:1561–1569. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ha Y, Kim D, Han S, Chon YE, Lee YB, Kim
MN, Lee JH, Park H, Rim KS and Hwang SG: Sarcopenia predicts
prognosis in patients with newly diagnosed hepatocellular
carcinoma, independent of tumor stage and liver function. Cancer
Res Treat. 50:843–851. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hirota K, Kawaguchi T, Koya S, Nagamatsu
A, Tomita M, Hashida R, Nakano D, Niizeki T, Matsuse H, Shiba N and
Torimura T: Clinical utility of the liver frailty index for
predicting muscle atrophy in chronic liver disease patients with
hepatocellular carcinoma. Hepatol Res. 50:330–341. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Imai K, Takai K, Watanabe S, Hanai T,
Suetsugu A, Shiraki M and Shimizu M: Sarcopenia impairs prognosis
of patients with hepatocellular carcinoma: The role of liver
functional reserve and tumor-related factors in loss of skeletal
muscle volume. Nutrients. 9:10542017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim YR, Park S, Han S, Ahn JH, Kim S, Sinn
DH, Jeong WK, Ko JS, Gwak MS and Kim GS: Sarcopenia as a predictor
of post-transplant tumor recurrence after living donor liver
transplantation for hepatocellular carcinoma beyond the Milan
criteria. Sci Rep. 8:71572018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi A, Kaido T, Hamaguchi Y, Okumura
S, Shirai H, Yao S, Kamo N, Yagi S, Taura K, Okajima H and Uemoto
S: Impact of sarcopenic obesity on outcomes in patients undergoing
hepatectomy for hepatocellular carcinoma. Ann Surg. 269:924–931.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kobayashi T, Kawai H, Nakano O, Abe S,
Kamimura H, Sakamaki A, Kamimura K, Tsuchiya A, Takamura M,
Yamagiwa S and Terai S: Rapidly declining skeletal muscle mass
predicts poor prognosis of hepatocellular carcinoma treated with
transcatheter intra-arterial therapies. BMC Cancer. 18:7562018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kotoh Y, Saeki I, Yamasaki T, Sasaki R,
Tanabe N, Oono T, Matsuda T, Hisanaga T, Matsumoto T, Hidaka I, et
al: Effect of handgrip strength on clinical outcomes of patients
with hepatocellular carcinoma treated with lenvatinib. Appl Sci.
10:54032020. View Article : Google Scholar
|
|
28
|
Kroh A, Uschner D, Lodewick T, Eickhoff
RM, Schöning W, Ulmer FT, Neumann UP and Binnebösel M: Impact of
body composition on survival and morbidity after liver resection in
hepatocellular carcinoma patients. Hepatobiliary Pancreat Dis Int.
18:28–37. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lanza E, Masetti C, Messana G, Muglia R,
Pugliese N, Ceriani R, Lleo de Nalda A, Rimassa L, Torzilli G,
Poretti D, et al: Sarcopenia as a predictor of survival in patients
undergoing bland transarterial embolization for unresectable
hepatocellular carcinoma. PLoS One. 15:e02323712020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee J, Cho Y, Park S, Kim JW and Lee IJ:
Skeletal muscle depletion predicts the prognosis of patients with
hepatocellular carcinoma treated with radiotherapy. Front Oncol.
9:10752019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Levolger S, van Vledder MG, Muslem R, Koek
M, Niessen WJ, de Man RA, de Bruin RW and Ijzermans JN: Sarcopenia
impairs survival in patients with potentially curable
hepatocellular carcinoma. J Surg Oncol. 112:208–213. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liao C, Li G, Bai Y, Zhou S, Huang L, Yan
M, Qiu F, Chen J, Wang Y, Tian Y and Chen S: Prognostic value and
association of sarcopenic obesity and systemic inflammatory indexes
in patients with hepatocellular carcinoma following hepatectomy and
the establishment of novel predictive nomograms. J Gastrointest
Oncol. 12:669–693. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Meister FA, Lurje G, Verhoeven S,
Wiltberger G, Heij L, Liu WJ, Jiang D, Bruners P, Lang SA, Ulmer
TF, et al: The role of sarcopenia and myosteatosis in short- and
long-term outcomes following curative-intent surgery for
hepatocellular carcinoma in a European cohort. Cancers (Basel).
14:7202022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Meza-Junco J, Montano-Loza AJ, Baracos VE,
Prado CM, Bain VG, Beaumont C, Esfandiari N, Lieffers JR and Sawyer
MB: Sarcopenia as a prognostic index of nutritional status in
concurrent cirrhosis and hepatocellular carcinoma. J Clin
Gastroenterol. 47:861–870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Salman A, Salman M, Moustafa A, Shaaban
HE, El-Mikkawy A, Labib S, Youssef A, Omar MG, Matter M and
Elkassar H: Impact of sarcopenia on two-year mortality in patients
with hcv-associated hepatocellular carcinoma after radiofrequency
ablation. J Hepatocell Carcinoma. 8:313–320. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Salman MA, Omar HSE, Mikhail HMS, Tourky
M, El-Ghobary M, Elkassar H, Omar MG, Matter M, Elbasiouny AM,
Farag AM, et al: Sarcopenia increases 1-year mortality after
surgical resection of hepatocellular carcinoma. ANZ J Surg.
90:781–785. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shiba S, Shibuya K, Katoh H, Koyama Y,
Okamoto M, Abe T, Ohno T and Nakano T: No deterioration in clinical
outcomes of carbon ion radiotherapy for sarcopenia patients with
hepatocellular carcinoma. Anticancer Res. 38:3579–3586. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takagi K, Yagi T, Yoshida R, Shinoura S,
Umeda Y, Nobuoka D, Kuise T, Watanabe N and Fujiwara T: Sarcopenia
and American society of anesthesiologists physical status in the
assessment of outcomes of hepatocellular carcinoma patients
undergoing hepatectomy. Acta Med Okayama. 70:363–370.
2016.PubMed/NCBI
|
|
39
|
Antonelli G, Gigante E, Iavarone M, Begini
P, Sangiovanni A, Iannicelli E, Biondetti P, Pellicelli AM,
Miglioresi L, Marchetti P, et al: Sarcopenia is associated with
reduced survival in patients with advanced hepatocellular carcinoma
undergoing sorafenib treatment. United European Gastroenterol J.
6:1039–1048. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Harimoto N, Shirabe K, Yamashita YI,
Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Maehara Y, Nishie A and
Yamanaka T: Sarcopenia as a predictor of prognosis in patients
following hepatectomy for hepatocellular carcinoma. Br J Surg.
100:1523–1530. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nishikawa H, Nishijima N, Enomoto H,
Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T,
Iijima H, et al: Prognostic significance of sarcopenia in patients
with hepatocellular carcinoma undergoing sorafenib therapy. Oncol
Lett. 14:1637–1647. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen BB, Liang PC, Shih TT, Liu TH, Shen
YC, Lu LC, Lin ZZ, Hsu C, Hsu CH, Cheng AL and Shao YY: Sarcopenia
and myosteatosis are associated with survival in patients receiving
immunotherapy for advanced hepatocellular carcinoma. Eur Radiol.
33:512–522. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Naganuma A, Hoshino T, Suzuki Y, Uehara D,
Kudo T, Ishihara H, Sato K, Kakizaki S, Yamada M and Takagi H:
Association between skeletal muscle depletion and sorafenib
treatment in male patients with hepatocellular carcinoma: A
retrospective cohort study. Acta Med Okayama. 71:291–299.
2017.PubMed/NCBI
|
|
44
|
Mardian Y, Yano Y, Ratnasari N, Choridah
L, Wasityastuti W, Setyawan NH and Hayashi Y: ‘Sarcopenia and
intramuscular fat deposition are associated with poor survival in
Indonesian patients with hepatocellular carcinoma: A retrospective
study’. BMC Gastroenterol. 19:2292019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Badran H, Elsabaawy MM, Ragab A, Aly RA,
Alsebaey A and Sabry A: Baseline sarcopenia is associated with lack
of response to therapy, liver decompensation and high mortality in
hepatocellular carcinoma patients. Asian Pac J Cancer Prev.
21:3285–3290. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hou GM, Jiang C, Du JP and Yuan KF:
Sarcopenia predicts an adverse prognosis in patients with combined
hepatocellular carcinoma and cholangiocarcinoma after surgery.
Cancer Med. 11:317–331. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Imai K, Takai K, Miwa T, Taguchi D, Hanai
T, Suetsugu A, Shiraki M and Shimizu M: Rapid depletion of
subcutaneous adipose tissue during sorafenib treatment predicts
poor survival in patients with hepatocellular carcinoma. Cancers
(Basel). 12:17952020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Endo K, Kuroda H, Kanazawa J, Sato T,
Fujiwara Y, Abe T, Sato H, Kooka Y, Oikawa T, Sawara K and Takikawa
Y: Impact of grip strength in patients with unresectable
hepatocellular carcinoma treated with lenvatinib. Cancers (Basel).
12:21462020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Choi K, Jang HY, Ahn JM, Hwang SH, Chung
JW, Choi YS, Kim JW, Jang ES, Choi GH and Jeong SH: The association
of the serum levels of myostatin, follistatin, and interleukin-6
with sarcopenia, and their impacts on survival in patients with
hepatocellular carcinoma. Clin Mol Hepatol. 26:492–505. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Harimoto N, Yoshizumi T, Shimokawa M,
Sakata K, Kimura K, Itoh S, Ikegami T, Ikeda T, Shirabe K and
Maehara Y: Sarcopenia is a poor prognostic factor following hepatic
resection in patients aged 70 years and older with hepatocellular
carcinoma. Hepatol Res. 46:1247–1255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kamachi S, Mizuta T, Otsuka T, Nakashita
S, Ide Y, Miyoshi A, Kitahara K, Eguchi Y, Ozaki I and Anzai K:
Sarcopenia is a risk factor for the recurrence of hepatocellular
carcinoma after curative treatment. Hepatol Res. 46:201–208. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang JX, Yan HT, Ding Y, Liu J, Liu S, Zu
QQ and Shi HB: Low psoas-muscle index is associated with decreased
survival in hepatocellular carcinoma treated with transarterial
chemoembolization. Ann Med. 54:1562–1569. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yabusaki N, Fujii T, Yamada S, Suzuki K,
Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M and Kodera Y:
Adverse impact of low skeletal muscle index on the prognosis of
hepatocellular carcinoma after hepatic resection. Int J Surg.
30:136–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fujiwara N, Nakagawa H, Kudo Y, Tateishi
R, Taguri M, Watadani T, Nakagomi R, Kondo M, Nakatsuka T, Minami
T, et al: Sarcopenia, intramuscular fat deposition, and visceral
adiposity independently predict the outcomes of hepatocellular
carcinoma. J Hepatol. 63:131–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Acosta LF, Galuppo R, García CR,
Villacorta E, Dugan A, Castellanos AL, Gedaly R and Lee JT:
Association between sarcopenia and AFP level in patients undergoing
liver transplantation for hepatocellular carcinoma. J Surg Res.
238:10–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yang J, Chen K, Zheng C, Chen K, Lin J,
Meng Q, Chen Z, Deng L, Yu H, Deng T, et al: Impact of sarcopenia
on outcomes of patients undergoing liver resection for
hepatocellular carcinoma. J Cachexia Sarcopenia Muscle.
13:2383–2392. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hamaguchi Y, Kaido T, Okumura S, Kobayashi
A, Shirai H, Yao S, Yagi S, Kamo N, Seo S, Taura K, et al:
Preoperative visceral adiposity and muscularity predict poor
outcomes after hepatectomy for hepatocellular carcinoma. Liver
Cancer. 8:92–109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Uojima H, Chuma M, Tanaka Y, Hidaka H,
Nakazawa T, Iwabuchi S, Kobayashi S, Hattori N, Ogushi K, Morimoto
M, et al: Skeletal muscle mass influences tolerability and
prognosis in hepatocellular carcinoma patients treated with
lenvatinib. Liver Cancer. 9:193–206. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Takada H, Kurosaki M, Nakanishi H,
Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K,
Komiyama Y, et al: Impact of pre-sarcopenia in sorafenib treatment
for advanced hepatocellular carcinoma. PLoS One. 13:e01988122018.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tan Y, Duan T, Li B, Zhang B, Zhu Y, Yan
K, Song J, Lv T, Yang J, Jiang L, et al: Sarcopenia defined by
psoas muscle index independently predicts long-term survival after
living donor liver transplantation in male recipients. Quant
Imaging Med Surg. 12:215–228. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim N, Yu JI, Park HC, Yoo GS, Choi C,
Hong JY, Lim HY, Lee J, Choi MS, Lee JE and Kim K: Incorporating
sarcopenia and inflammation with radiation therapy in patients with
hepatocellular carcinoma treated with nivolumab. Cancer Immunol
Immunother. 70:1593–1603. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Iritani S, Imai K, Takai K, Hanai T, Ideta
T, Miyazaki T, Suetsugu A, Shiraki M, Shimizu M and Moriwaki H:
Skeletal muscle depletion is an independent prognostic factor for
hepatocellular carcinoma. J Gastroenterol. 50:323–232. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Voron T, Tselikas L, Pietrasz D, Pigneur
F, Laurent A, Compagnon P, Salloum C, Luciani A and Azoulay D:
Sarcopenia impacts on short- and long-term results of hepatectomy
for hepatocellular carcinoma. Ann Surg. 261:1173–1183. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bischoff-Ferrari HA, Orav JE, Kanis JA,
Rizzoli R, Schlögl M, Staehelin HB, Willett WC and Dawson-Hughes B:
Comparative performance of current definitions of sarcopenia
against the prospective incidence of falls among community-dwelling
seniors age 65 and older. Osteoporos Int. 26:2793–2802. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Williams GR, Dunne RF, Giri S, Shachar SS
and Caan BJ: Sarcopenia in the older adult with cancer. J Clin
Oncol. 39:2068–2078. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Giallauria F, Cittadini A, Smart NA and
Vigorito C: Resistance training and sarcopenia. Monaldi Arch Chest
Dis. 84:7382016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fan J, Kou X, Yang Y and Chen N:
MicroRNA-regulated proinflammatory cytokines in sarcopenia.
Mediators Inflamm. 2016:14386862016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sinclair M, Grossmann M, Angus PW,
Hoermann R, Hey P, Scodellaro T and Gow PJ: Low testosterone as a
better predictor of mortality than sarcopenia in men with advanced
liver disease. J Gastroenterol Hepatol. 31:661–667. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Phillips T and Leeuwenburgh C: Muscle
fiber specific apoptosis and TNF-alpha signaling in sarcopenia are
attenuated by life-long calorie restriction. FASEB J. 19:668–670.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Anderson LJ, Liu H and Garcia JM: Sex
differences in muscle wasting. Adv Exp Med Biol. 1043:153–197.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Janssen I, Heymsfield SB, Wang ZM and Ross
R: Skeletal muscle mass and distribution in 468 men and women aged
18–88 yr. J Appl Physiol (1985). 89:81–88. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
